FANCE antibody Ab host: Goat
- Known as:
- FANCE (anti-) Antibody production species: Goat
- Catalog number:
- 'AP31970PU-N
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- FANCE antibody host: Goat
Related genes to: FANCE antibody Ab host: Goat
- Gene:
- FANCE NIH gene
- Name:
- FA complementation group E
- Previous symbol:
- FACE
- Synonyms:
- FAE
- Chromosome:
- 6p21.31
- Locus Type:
- gene with protein product
- Date approved:
- 1996-04-09
- Date modifiied:
- 2019-04-23
- Gene:
- PPP1R18 NIH gene
- Name:
- protein phosphatase 1 regulatory subunit 18
- Previous symbol:
- KIAA1949
- Synonyms:
- phostensin
- Chromosome:
- 6p21.33
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-02
- Date modifiied:
- 2016-10-05
Related products to: FANCE antibody Ab host: Goat
Related articles to: FANCE antibody Ab host: Goat
- Non-functioning pituitary adenoma (NFPA) is the most common pituitary tumor. Due to the lack of hormone hypersecretion, it is often diagnosed when the tumor enlarges and gives compression symptoms. Surgical resection is the primary treatment modality; however, complete remission rates remain suboptimal. In this study, we aimed to investigate differentially expressed genes (DEGs) that may be involved in NFPA pathogenesis. - Source: PubMed
Uzkul Nisa DevrimAkkoyunlu Deniz SunnetciCabuk BurakIsik Elif BusraIskenderoglu Elmas TunaKeskin Seda ErenCine NaciSavli Hakan - More than 80% of patients who meet clinical criteria for hereditary breast and ovarian cancer (HBOC) do not show pathogenic variants in BRCA1, BRCA2, and other diagnostically consented core genes. We hypothesized that variants in further DNA repair genes, cryptic genomic alterations, or polygenic factors may explain HBOC risk. We studied 134 patients with breast cancer and/or ovarian cancer by the use of whole genome sequencing (WGS), whole transcriptome sequencing (WTS), optical genome mapping (OGM), and mobile element analysis. We identified (likely) pathogenic variants in DNA repair genes in 18 patients, including several RECQ helicase and other DNA repair genes, an intragenic FANCM deletion, and six rare mobile element insertions (MEIs) in DNA repair genes. Incorporating PRS306 shifted estimated lifetime breast cancer risk by ≥5 percentage points in a subset of women (n = 75), including carriers of rare variants in DNA repair genes, resulting in both upward and downward risk estimation. - Source: PubMed
Publication date: 2026/06/30
Allister B AldrigeHofmann WinfriedLühmann Jonathan LSander BjörnWendeburg LenaSchmidt GunnarAuber BerndMorlot SusanneWallaschek Hannahdi Donato NataliyaSchlegelberger BrigitteGolas Monika MSteinemann Doris - Performing germline genetic testing of family members following the identification of an individual with a pathogenic variant in a cancer predisposition gene, a process known as cascade testing, is a critical step in maximizing the preventive benefit of genetic testing for hereditary cancer. - Source: PubMed
Publication date: 2026/06/01
Namey EliaHorton CarolynDudley BethCarraway CassidyKomala TimothyMilliard CarrieNamey TaraKarloski EveBrand Randall - Genetic testing for known familial pathogenic or likely pathogenic germline variants in cancer susceptibility genes is central to identifying relatives at heightened risk for cancer. However, current data suggest that uptake of this practice referred to as "cascade testing" remains suboptimal. Research demonstrates that healthcare providers can alleviate barriers to cascade testing by providing informational resources to facilitate patient-mediated sharing of their genetic test results with their at-risk relatives. - Source: PubMed
Publication date: 2026/06/27
Riefski KatieAeilts AmberSpencer AlexandraFriedman SueCooper JuliaSenter Leigha - Castration-resistant prostate cancer (CRPC) poses significant therapeutic challenges due to its aggressive nature and limited effective treatments. Although PARP inhibitor olaparib has been approved for metastatic CRPC patients bearing BRCA1/2 mutations, its application is confined to this specific patient subpopulation. The induction of "BRCAness" feature in CRPC patients without BRCA1/2 mutations becomes a significant challenge. - Source: PubMed
Publication date: 2026/06/17
Li JiaxuanSun JingyaTan WeisongLi GuoqiXiao WenjieWu JiajunYang WeiChen ChangqingLi YangLiu JiakuanLiu YuanyuLiu DongChen Xiao-HuaZhu RujianHuang RuiminYan Jun